Poster: ECR 2013 / C-0687 / Study on accurate dose mapping system with radiophotoluminescence glass dosimeter (RPLD) measuring the direct patient entrance dose in cardiac interventional procedures. by: M. Kato1, K. Chida2, T. Moritake3, Y. Koguchi4, T. Sato1, H. Oosaka1, T. Tosa1, K. Kadowaki1; 1Akita/JP, 2Sendai/JP, 3Tsukuba/JP, 4Higashiibarakigun Oaraimachi/JP
In order to determine the relationship between efficacy and plasma level of flecainide in ventricular premature contractions (VPC), a study was carried out through multipleadministration method in 15 patients with VPC at dose level of 50mg b.i.d., 100mg b.i.d., or 150mg b.i.d. The results of this study were as follows.1) Flecainide was effective in 50% of patients at 50mg b.i.d. and all patients at 100 mg b.i.d. and 150mg b.i.d. Judging from the supression ratio of VPC by flecainide, the dose level from 50mg b.i.d. to 100mg b.i.d. seems to be appropriate for clinical applications.2) The minimum effective plasma level may be placed at 200ng/ml, and a reliable suppressive effect on VPC can be expected of flecainide at plasma level of 400ng/ml or more.3) Plasma level at steady state increased dose dependently up to 100mg b.i.d., though the plasma level at 150mg b.i.d. was greatly elevated to the extent of 1, 000ng/ml or more.4) Six laboratory data in 3 patients showed abnormal values, but the elevations in GOT, GPT and BUN seemed to have slight if any relationship to the treatment. The PQ and QTc intervals on the electrocardiogram were prolonged significantly.Therefore, it may be concluded that flecainide is a useful drug for the treatment of VPC and that 100mg b.i.d. is suitable as a usual clinical dose.
Recent outcomes based on surgical long-term follow-up of patients with gastric cancer using current staging systems have not been fully evaluated.A total of 1357 patients with primary gastric carcinoma (911 males and 446 females, ranging in age from 20 to 87 years; average 59.1 years) who had undergone gastric resection between 1986 and 1996 were examined with respect to their clinicopathological features, surgical procedures and patient survival according to Japanese and UICC-TNM classifications.The 5-year survival rate was 95.3% for stage Ia, 85.5% for stage Ib, 73.8% for stage II, 45.7% for stage IIIa, 20.9% for stage IIIb, 17.3% for stage IVa and 5.8% for stage IVb (8.8% for IVa and IVb) on the Japanese classification. By way of contrast, the 5-year survival rate was 95.6% for stage Ia, 85.0% for stage Ib, 72.1% for stage II, 49.3% for stage IIIa, 30.2% for stage IIIb and 12.0% for stage IV on the TNM classification.Although minor problems are associated with both the Japanese and TNM classification systems, both appear to be clinically significant and appropriate independent predictors of prognosis. The findings of the present study provide important information for comparing results among different institutes and for introducing new clinical trials for gastric cancer at the beginning of the new century.
